
Subject: update intercytex

Posted by [christian77](#) on Thu, 18 Sep 2008 07:23:58 GMT

[View Forum Message](#) <> [Reply to Message](#)

dachte ich mach nen neuen thread auf, weil der alte schon so zerfurcht ist...

<http://www.intercytex.com/icx/news/releases/2008/2008-09-18/>

Intercytex Group plc – Interim results for the six months ended 30 June 2008

18th September 2008

Intercytex Group plc (LSE: ICX), the regenerative medicine company developing innovative products to restore skin and hair, announces its interim results for the six months ended 30 June 2008.

PRODUCT HIGHLIGHTS

Cyzact® (ICX-PRO) - healing chronic wounds

- * Phase III trial in venous leg ulcers fully recruited; data expected to be announced around the end of Q1/2009 with filing of the BLA in the second half of that year

- * Final positive Phase II data from diabetic foot ulcer trial of Cyzact® presented at EWMA conference in Lisbon

VAVELTA® - natural repair for damaged skin

- * First commercial sales of VAVELTA® commenced in June; rollout of distribution network underway with over 15 clinics now accredited

- * Positive final data from two Phase II trials of VAVELTA® presented in June at FACE congress in London, UK

- * Further positive responses being generated from field trials of VAVELTA® conducted by the Clinical Practice Group with around 50 patients treated by this group to date

- * Treatment commenced in a third Phase II trial for burns scars (including contractures); trial extended to up to 30 patients with additional centres being enrolled

ICX-SKN - skin grafts for acute wounds

- * Phase I study showed integration of graft in all 12 patients persisting for up to 6 months

- * Product being reformulated for trauma and burns applications for US Phase II clinical trial as part of the AFIRM award

ICX-TRC - hair regeneration

- * Data from the Phase II trial shows increase in hair count in 11 out of 14 (79%) evaluable subjects at 24 weeks

CORPORATE AND FINANCIAL HIGHLIGHTS

* Placing of new shares to existing shareholders completed on 8th September 2008 raising £2.75m gross

* Intercytex the only non-US participant in a group awarded substantial funding to establish US Armed Forces Institute of Regenerative Medicine (AFIRM); initial funding available to support development of ICX-SKN for burns in the US

* Awarded grant from the Technology Strategy Board of £285k over 3 years to assist with development of strategies for preservation and storage of cell therapy products

* Positive report received from Human Tissue Authority following inspection of our Manchester GMP facility

* Loss before tax for the six months ended 30 June 2008 of £6.59m (H1 2007: £6.04m)

* Cash and cash equivalents and liquid investments at 30 June 2008 of £6.36m (H1 2007: £17.55m)
